Collegium Pharmaceutical issues 2026 financial guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St set to climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Triller to acquire SpaceX exposure as treasury asset via fund structure
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Collegium Provides 2026 Financial Guidance and Business Update
January 8, 2026 8:00 AM ESTProduct Revenues, Net Expected in the Range of $805 Million to $825 Million
Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million
Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million
STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update.
2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum for continued success,... More
